Rheumatoid arthritis

You are here : Home > Formulary Search > Rheumatoid arthritis

Documentation

Guidelines (Local)

Rheumatoid Arthritis High cost immunomodulator drug pathway Apr-24.pdf

Guidelines (National)

British Society Rheumatology (BSR) non-biologic DMARD guidelines Feb-17.pdf

Webpage

MHRA risk warning - JAK inhibitors - Apr 23

Drugs

Below are listed all drugs that are used to treat Rheumatoid arthritis.

Committee Recommendations (1)

05 Jul 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated Rheumatology Immunomodulator pathways (axial spondyloarthritis, psoriatic arthritis and rheumatoid arthritis (moderate and severe).

Guideline Profile

Indication :

Rheumatoid arthritis

Keywords :

Abatacept, adalimumab, etanercept, anakinra, baricitinib, certolizumab, golimumab, infliximab, rituximab, tocilizumab, sarilumab, tofacitinib, upadacitinib, filgotinib, penicillamine, prednisone, sodium aurothiomalate, RA, Immunomodulator, Protein Kinase Inhibitor, JAK inhibitor, Janus Kinase, NICE TA, JAKI, anti-TNF, TNF alpha, b-cell, IL 6, interleukin inhibitor, biosimilar, biologic,

Brand Names Include :

MabThera, Truxima, Rixathon, Ruzience, Orencia, Humira, Hyrimoz, Imraldi, Amgevita, Hulio, Yuflyma, Idacio, Kineret, Olumiant, Cimzia, Enbrel, Benepali, Erelzi, Jyseleca, Simponi, Remicade, Inflectra, Remsima, Flixabi, Zessly, Distamine, Lodotra, Kevzara, Myocrisin, RoActemRA, Tyenne, Xeljanz, Rinvoq

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Supporting Documents :